{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:09:49Z","timestamp":1790507389895,"version":"4.1.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.20064","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T15:35:01Z","timestamp":1629128101000},"page":"e2120064","source":"Crossref","is-referenced-by-count":56,"title":["Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding"],"prefix":"10.1001","volume":"4","author":[{"given":"Gregory Y. H.","family":"Lip","sequence":"first","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom"},{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"},{"name":"Ochsner Clinic Foundation, Department of Hospital Medicine, New Orleans, Louisiana"},{"name":"The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison V.","family":"Keshishian","sequence":"additional","affiliation":[{"name":"STATinMED Research, Ann Arbor, Michigan"},{"name":"New York City College of Technology, City University of New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, Lawrenceville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amiee","family":"Kang","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, Lawrenceville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol D.","family":"Dhamane","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, Lawrenceville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Luo","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., Groton, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Klem","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, Lawrenceville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Ferri","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, Lawrenceville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Jiang","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, Lawrenceville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin","family":"Yuce","sequence":"additional","affiliation":[{"name":"New York City College of Technology, City University of New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Deitelzweig","sequence":"additional","affiliation":[{"name":"Ochsner Clinic Foundation, Department of Hospital Medicine, New Orleans, Louisiana"},{"name":"The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"issue":"2","key":"zoi210593r1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10654-018-0415-7","article-title":"Direct comparative effectiveness and safety between non\u2013vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.","volume":"34","author":"Li","year":"2019","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"zoi210593r2","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1160\/TH16-11-0876","article-title":"Stroke prevention in atrial fibrillation: past, present and future\u2014comparing the guidelines and practical decision-making.","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb Haemost"},{"issue":"11","key":"zoi210593r3","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.3748\/wjg.v23.i11.1954","article-title":"Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management.","volume":"23","author":"Cheung","year":"2017","journal-title":"World J Gastroenterol"},{"key":"zoi210593r4","doi-asserted-by":"publisher","first-page":"h1857","DOI":"10.1136\/bmj.h1857","article-title":"Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.","volume":"350","author":"Abraham","year":"2015","journal-title":"BMJ"},{"issue":"9","key":"zoi210593r5","first-page":"968","article-title":"Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation.","volume":"23","author":"Adeboyeje","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"zoi210593r6","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation.","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"zoi210593r7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi210593r8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi210593r9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi210593r10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"5","key":"zoi210593r11","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/jcm9051398","article-title":"Non\u2013vitamin K antagonist oral anticoagulants and the gastrointestinal bleeding risk in real-world studies.","volume":"9","author":"Anghel","year":"2020","journal-title":"J Clin Med"},{"issue":"58","key":"zoi210593r12","doi-asserted-by":"publisher","first-page":"98898","DOI":"10.18632\/oncotarget.v8i58","article-title":"Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation.","volume":"8","author":"Chan","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"zoi210593r13","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients.","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke"},{"issue":"6","key":"zoi210593r14","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH17-01-0068","article-title":"Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in \u201creal-world\u201d clinical practice: a propensity-matched analysis of 76,940 patients.","volume":"117","author":"Li","year":"2017","journal-title":"Thromb Haemost"},{"issue":"1","key":"zoi210593r15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCOUTCOMES.113.000371","article-title":"Validity of International Classification of Disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation.","volume":"8","author":"Thigpen","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"zoi210593r16","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use.","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"25","key":"zoi210593r17","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"7","key":"zoi210593r18","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.v33.7","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments.","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"1","key":"zoi210593r19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/CIRCULATIONAHA.119.041296","article-title":"Patients with atrial fibrillation taking nonsteroidal anti-inflammatory drugs and oral anticoagulants in the ARISTOTLE trial.","volume":"141","author":"Dalgaard","year":"2020","journal-title":"Circulation"},{"key":"zoi210593r20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ahj.2020.01.010","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease.","volume":"223","author":"Weir","year":"2020","journal-title":"Am Heart J"},{"issue":"10","key":"zoi210593r21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.amjmed.2020.03.019","article-title":"Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mAFA-II randomized trial.","volume":"133","author":"Guo","year":"2020","journal-title":"Am J Med"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2783045\/lip_2021_oi_210593_1631547210.69185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T15:23:32Z","timestamp":1631719412000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2783045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.20064","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]}}}